Synergistic effect of 17-allylamino-17-demethoxygeldanamycin with dehydroxymethylepoxyquinomicin on the human anaplastic thyroid carcinoma cell line KTC2

The use of targeted inhibitors has shown promise as an effective approach in cancer therapy. However, therapies based only on one drug, such 17-allylamino-17-demethoxygeldanamycin (17-AAG), have limited success, partly because cells engage alternate pathways for survival and proliferation. In the present study, we evaluated whether dehydroxymethylepoxyquinomicin (DHMEQ), a nuclear factor ?B (NF-?B) inhibitor, can enhance antitumor activities 17-AAG, 90 kDa heat shock protein (Hsp90) anaplastic thyroid cell line KTC2. We examined effect combined drug treatment vs single survival. Isobologram analysis was performed to distinguish additive synergistic effects combination. Western blotting investigate apoptosis markers: caspase 3, poly(ADP-ribose) polymerase-one (PARP-1), B-cell lymphoma-extra large (Bcl-XL), X-linked inhibitor (XIAP) cellular 2 (cIAP-2). Compared monotherapy, enhanced growth-inhibitory manner strongly potentiated apoptosis. These results demonstrate first vitro evidence that combination Hsp90 NF-?B is more modality inhibiting proliferation carcinoma than either agent alone, warranting further investigations.